Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives

References

• Kohler L, Puertollano R, Raben N. Pompe Disease: from Basic Science to Therapy. Neurotherapeutics. 2018;15(4):928–942. doi:10.1007/s13311-018-0655-y
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267–288. doi:10.1097/01.gim.0000218152.87434.f3
   PubMed Web of Science ®Google Scholar
• Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, et al. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet. 2012;160c(1):59–68. doi:10.1002/ajmg.c.31318
   PubMed Web of Science ®Google Scholar
• Sarah B, Giovanna B, Emanuela K, et al. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis. J Neurol. 2022;269(2):733–741.
   PubMed Web of Science ®Google Scholar
• Stockton DW, Kishnani P, van der Ploeg A, et al. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. J Neurol. 2020;267(10):3038–3053.
   PubMed Web of Science ®Google Scholar
• van Gelder C, Plug I, Kroos M, et al. A higher dose of enzyme therapy in patients with classic infantile Pompe disease seems to improve ventilator-free survival and motor function. BMC Musculoskelet Disord. 2013;14(Suppl 2):19. doi:10.1186/1471-2474-14-S2-P19
   PubMedGoogle Scholar
• Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26–33.
   PubMed Web of Science ®Google Scholar
• Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13(8):729–736.
   PubMed Web of Science ®Google Scholar
• Mendelsohn NJ, Messinger YH, Rosenberg AS, et al. Elimination of antibodies to recombinant enzyme in Pompe’s disease. N Engl J Med. 2009;360(2):194–195.
   PubMed Web of Science ®Google Scholar
• Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012;14(1):135–142. doi:10.1038/gim.2011.4
   PubMed Web of Science ®Google Scholar
• Spiesshoefer J, Henke C, Kabitz HJ, et al. The nature of respiratory muscle weakness in patients with late-onset Pompe disease. Neuromuscul Disord. 2019;29(8):618–627. doi:10.1016/j.nmd.2019.06.011
   PubMed Web of Science ®Google Scholar
• Dupé C, Lefeuvre C, Solé G, et al. Macroglossia: a potentially severe complication of late-onset Pompe disease. Eur J Neurol. 2022;29(7):2121–2128. doi:10.1111/ene.15330
   PubMed Web of Science ®Google Scholar
• Brenn BR, Theroux MT, Shah SA, et al. Critical airway stenosis in an adolescent male with pompe disease and thoracic lordosis: a case report. A Case Rep. 2017;9(7):199–203.
   Google Scholar
• Burghaus L, Liu W, Neuen-Jacob E, et al. Glykogenose Typ II (M. Pompe). Selektiver Befall der Atemmuskulatur --Eine seltene Erstmanifestation [Glycogenesis Type II (M. Pompe). Selective failure of the respiratory musculature--a rare first symptom]. Nervenarzt. 2006;77(2):181–2, 185–6. German. doi:10.1007/s00115-005-2005-7
   Google Scholar
• Carlier RY, Laforet P, Wary C, et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: involvement patterns. Neuromuscul Disord. 2011;21(11):791–799. doi:10.1016/j.nmd.2011.06.748
   PubMed Web of Science ®Google Scholar
• Jones HN, Muller CW, Lin M, et al. Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia. 2010;25(4):277–283. doi:10.1007/s00455-009-9252-x
   PubMed Web of Science ®Google Scholar
• Jones HN, Crisp KD, Asrani P, et al. Quantitative assessment of lingual strength in late-onset Pompe disease. Muscle Nerve. 2015;51(5):731–735. doi:10.1002/mus.24523
   PubMed Web of Science ®Google Scholar
• Gambetti P, DiMauro S, Baker L. Nervous system in Pompe’s disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol. 1971;30(3):412–430. doi:10.1097/00005072-197107000-00008
   PubMed Web of Science ®Google Scholar
• Falk DJ, Todd AG, Lee S, et al. Peripheral nerve and neuromuscular junction pathology in Pompe disease. Hum Mol Genet. 2015;24(3):625–636. doi:10.1093/hmg/ddu476
   PubMed Web of Science ®Google Scholar
• Byrne BJ, Fuller DD, Smith BK, et al. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. Ann Transl Med. 2019;7(13):290. doi:10.21037/atm.2019.05.56
   PubMed Web of Science ®Google Scholar
• Yang C-F, Niu D-M, Tai S-K, et al. Airway abnormalities in very early treated infantile-onset Pompe disease: a large-scale survey by flexible bronchoscopy. Am J Med Genet A. 2020;182(4):721–729. doi:10.1002/ajmg.a.61481
   PubMed Web of Science ®Google Scholar
• Yang CF, Niu D-M, Jeng M-J, et al. Late-onset Pompe disease with left-sided bronchomalacia. Respir Care. 2015;60(2):e26–9. doi:10.4187/respcare.03419
   PubMed Web of Science ®Google Scholar
• Boentert M, Karabul N, Wenninger S, et al. Sleep-related symptoms and sleep-disordered breathing in adult Pompe disease. Eur J Neurol. 2015;22(2):369–76, e27. doi:10.1111/ene.12582
   PubMed Web of Science ®Google Scholar
• Berger KI, Chan Y, Rom WN, et al. Progression from respiratory dysfunction to failure in late-onset Pompe disease. Neuromuscul Disord. 2016;26(8):481–489.
   PubMed Web of Science ®Google Scholar
• Kansagra S, Austin S, DeArmey S, et al. Polysomnographic findings in infantile Pompe disease. Am J Med Genet A. 2013;161a(12):3196–3200. doi:10.1002/ajmg.a.36227
   PubMedGoogle Scholar
• Rowley JA, Zahn BR, Babcock MA, et al. The effect of rapid eye movement (REM) sleep on upper airway mechanics in normal human subjects. J Physiol. 1998;510(Pt 3):963–976. doi:10.1111/j.1469-7793.1998.00963.x
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148(5):671–676. doi:10.1016/j.jpeds.2005.11.033
   PubMed Web of Science ®Google Scholar
• Bay LB, Denzler I, Durand C¸ et al. Infantile-onset Pompe disease: diagnosis and management. Arch Argent Pediatr. 2019;117(4):271–278. doi:10.5546/aap.2019.eng.271
   PubMed Web of Science ®Google Scholar
• van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–340. doi:10.1542/peds.112.2.332
   PubMed Web of Science ®Google Scholar
• Moravej H, Karamizadeh Z, Paran M. The outcome of infantile onset pompe disease in South of Iran. Iran J Pediatr. 2016;26(1):e4473. doi:10.5812/ijp.4473
   PubMed Web of Science ®Google Scholar
• Owens P, Wong M, Bhattacharya K, et al. Infantile-onset Pompe disease: a case series highlighting early clinical features, spectrum of disease severity and treatment response. J Paediatr Child Health. 2018;54(11):1255–1261.
   PubMed Web of Science ®Google Scholar
• Marsden D. Infantile onset Pompe disease: a report of physician narratives from an epidemiologic study. Genet Med. 2005;7(2):147–150.
   PubMed Web of Science ®Google Scholar
• van der Beek NA, de Vries JM, Hagemans ML, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88.
   PubMed Web of Science ®Google Scholar
• Mellies U, Ragette R, Schwake C, et al. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology. 2001;57(7):1290–1295.
   PubMed Web of Science ®Google Scholar
• Sixel BS, Silva LD, Cavalcanti NC, et al. Respiratory manifestations in late-onset Pompe disease: a case series conducted in Brazil. J Bras Pneumol. 2017;43(1):54–59.
   PubMed Web of Science ®Google Scholar
• Boentert M, Prigent H, Várdi K, et al. Practical recommendations for diagnosis and management of respiratory muscle weakness in late-onset Pompe disease. Int J Mol Sci. 2016;17:10.
   Web of Science ®Google Scholar
• Chien YH, Lee NC, Huang HJ, et al. Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr. 2011;158(6):1023–1027.e1.
   PubMed Web of Science ®Google Scholar
• Schoser B, Stewart A, Kanters S, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2017;264(4):621–630.
   PubMed Web of Science ®Google Scholar
• Margolis ML, Howlett P, Goldberg R, et al. Obstructive sleep apnea syndrome in acid maltase deficiency. Chest. 1994;105(3):947–949.
   PubMed Web of Science ®Google Scholar
• Böing S, Randerath WJ. Chronic hypoventilation syndromes and sleep-related hypoventilation. J Thorac Dis. 2015;7(8):1273–1285.
   PubMed Web of Science ®Google Scholar
• Pellegrini N, Laforet P, Orlikowski D, et al. Respiratory insufficiency and limb muscle weakness in adults with Pompe’s disease. Eur Respir J. 2005;26(6):1024–1031.
   PubMed Web of Science ®Google Scholar
• Boentert M, Dräger B, Glatz C, et al. Sleep-Disordered Breathing and Effects of Noninvasive Ventilation in Patients with Late-Onset Pompe Disease. J Clin Sleep Med. 2016;12(12):1623–1632.
   PubMed Web of Science ®Google Scholar
• Veneruso G, Azzari C, Calandi C, Franchini V, Sabatini C, Vierucci A. Valutazione della funzionalità respiratoria in pazienti affetti da distrofia muscolare di Duchenne [Evaluation of the respiratory function in patients with Duchenne’s muscular dystrophy]. Pediatr Med Chir. 1987;9(1):15–19. Italian.
   PubMedGoogle Scholar
• Pennati F, LoMauro A, D’Angelo MG, Aliverti A. Non-invasive respiratory assessment in Duchenne muscular dystrophy: from clinical research to outcome measures. Life. 2021;11(9):1.
   Google Scholar
• Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319–333.
   PubMed Web of Science ®Google Scholar
• Katz S, Arish N, Rokach A, Zaltzman Y, Marcus EL. The effect of body position on pulmonary function: a systematic review. BMC Pulm Med. 2018;18(1):159.
   PubMed Web of Science ®Google Scholar
• MacKintosh EW, Chen ML, Benditt JO. Lifetime care of Duchenne muscular dystrophy. Sleep Med Clin. 2020;15(4):485–495.
   PubMed Web of Science ®Google Scholar
• Berger KI, Kanters S, Jansen JP, et al. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis. J Neurol. 2019;266(9):2312–2321.
   PubMed Web of Science ®Google Scholar
• Laveneziana P, Albuquerque A, Aliverti A, et al. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J. 2019;53(6):1.
   Web of Science ®Google Scholar
• Polkey MI, Green M, Moxham J. Measurement of respiratory muscle strength. Thorax. 1995;50(11):1131–1135.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002;166(4):518–624.
   PubMedGoogle Scholar
• Evans JA, Whitelaw WA. The assessment of maximal respiratory mouth pressures in adults. Respir Care. 2009;54(10):1348–1359.
   PubMed Web of Science ®Google Scholar
• Uldry C, Fitting JW. Maximal values of sniff nasal inspiratory pressure in healthy subjects. Thorax. 1995;50(4):371–375.
   PubMed Web of Science ®Google Scholar
• Pitts T, Bordelon R, Huff A, Byrne BJ, Smith BK. Cough effectiveness and pulmonary hygiene practices in patients with pompe disease. Lung. 2019;197(1):1–8.
   PubMed Web of Science ®Google Scholar
• Prigent H, et al. Supine volume drop and diaphragmatic function in adults with Pompe disease. Eur Respir J. 2012;39(6):1545–1546.
   PubMed Web of Science ®Google Scholar
• Reyes-Leiva D, Alonso-Pérez J, Mayos M, et al. Correlation between respiratory accessory muscles and diaphragm pillars MRI and pulmonary function test in late-onset pompe disease patients. Front Neurol. 2021;12:621257.
   PubMed Web of Science ®Google Scholar
• Meng P, Ogna A, Fayssoil A. M mode ultrasound and tissue Doppler imaging to assess diaphragm feature in late onset pompe disease. Neurol Int. 2020;12(3):55–58.
   PubMed Web of Science ®Google Scholar
• Ruggeri P, Lo Monaco L, Musumeci O, et al. Ultrasound assessment of diaphragm function in patients with late-onset Pompe disease. Neurol Sci. 2020;41(8):2175–2184.
   PubMed Web of Science ®Google Scholar
• Sarwal A, Walker FO, Cartwright MS. Neuromuscular ultrasound for evaluation of the diaphragm. Muscle Nerve. 2013;47(3):319–329.
   PubMed Web of Science ®Google Scholar
• D’Cruz RF, Murphy PB, Kaltsakas G. Sleep disordered breathing and chronic obstructive pulmonary disease: a narrative review on classification, pathophysiology and clinical outcomes. J Thorac Dis. 2020;12(Suppl 2):S202–s216.
   PubMedGoogle Scholar
• Shah NM, Sharma L, Ganeshamoorthy S, Kaltsakas G. Respiratory failure and sleep-disordered breathing in late-onset Pompe disease: a narrative review. J Thorac Dis. 2020;12(Suppl 2):S235–s247.
   PubMedGoogle Scholar
• Rosenow EC, Engel AG. Acid maltase deficiency in adults presenting as respiratory failure. Am J Med. 1978;64(3):485–491.
   PubMed Web of Science ®Google Scholar
• Jones HN, Hobson-Webb LD, Kuchibhatla M, et al. Tongue weakness and atrophy differentiates late-onset Pompe disease from other forms of acquired/hereditary myopathy. Mol Genet Metab. 2021;133(3):261–268.
   PubMed Web of Science ®Google Scholar
• Wang TH, Soong WJ, Niu DM, et al. Airway abnormalities and pulmonary complications in long-term treated late-onset Pompe disease: diagnostic and interventional by flexible bronchoscopy. Pediatr Pulmonol. 2022;57(1):185–192.
   PubMed Web of Science ®Google Scholar
• Keeler AM, Liu D, Zieger M, et al. Airway smooth muscle dysfunction in Pompe (Gaa(-/-)) mice. Am J Physiol Lung Cell Mol Physiol. 2017;312(6):L873–l881.
   PubMed Web of Science ®Google Scholar
• Spiesshoefer J, Runte M, Heidbreder A, et al. Sleep-disordered breathing and effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with myotonic dystrophy type I. Neuromuscul Disord. 2019;29(4):302–309.
   PubMed Web of Science ®Google Scholar
• Spiesshoefer J, Lutter R, Kabitz HJ, et al. Respiratory muscle function tests and diaphragm ultrasound predict nocturnal hypoventilation in slowly progressive myopathies. Front Neurol. 2021;12:731865.
   PubMed Web of Science ®Google Scholar
• Smith LJ, Horsley A, Bray J, et al. The assessment of short and long term changes in lung function in CF using (129)Xe MRI. Eur Respir J. 2020; 2020:1.
   Google Scholar
• Higano NS, Ruoss JL, Woods JC. Modern pulmonary imaging of bronchopulmonary dysplasia. J Perinatol. 2021;41(4):707–717.
   PubMed Web of Science ®Google Scholar
• Lin NY, Roach DJ, Willmering MM, et al. (129)Xe MRI as a measure of clinical disease severity for pediatric asthma. J Allergy Clin Immunol. 2021;147(6):2146–2153.e1.
   PubMed Web of Science ®Google Scholar
• Walkup LL, Myers K, El-Bietar J, et al. 129Xe MRI detects ventilation deficits in pediatric stem-cell transplant patients unable to perform spirometry. Eur Respir J. 2019;2019:1.
   Google Scholar
• Wang Z, Robertson SH, Wang J, et al. Quantitative analysis of hyperpolarized (129) Xe gas transfer MRI. Med Phys. 2017;44(6):2415–2428.
   PubMed Web of Science ®Google Scholar
• Wang Z, Bier EA, Swaminathan A, et al. Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. Eur Respir J. 2019;54(6):1.
   Web of Science ®Google Scholar
• Willmering MM, Walkup LL, Niedbalski PJ, et al. Pediatric (129) Xe Gas-Transfer MRI-feasibility and applicability. J Magn Reson Imaging. 2022;56(4):1207–1219.
   PubMed Web of Science ®Google Scholar
• Bier EA, Wang Z, Chalian H, et al. Noninvasive diagnosis of pulmonary hypertension with hyperpolarized 129Xe magnetic resonance imaging and spectroscopy. ERJ Open Res. 2022;2022:00035–2022.
   Google Scholar
• Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a Phase I/II clinical trial. Genet Med. 2001;3(2):132–138.
   PubMed Web of Science ®Google Scholar
• Khan AA, Case LE, Herbert M, et al. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. Genet Med. 2020;22(5):898–907.
   PubMed Web of Science ®Google Scholar
• ElMallah MK, Desai AK, Nading EB, et al. Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: a case series. Pediatr Pulmonol. 2020;55(3):674–681.
   PubMed Web of Science ®Google Scholar
• Hundsberger T, Rösler KM, Findling O. Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis. J Neurol. 2014;261(9):1684–1690.
   PubMed Web of Science ®Google Scholar
• Vianello A, Semplicini C, Paladini L, et al. Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. Lung. 2013;191(5):537–544.
   PubMed Web of Science ®Google Scholar
• Sayeed N, Sharma P, Abdelhalim M, Mukherjee R. Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in adult Pompe disease. Respirol Case Rep. 2015;3(4):159–161.
   PubMedGoogle Scholar
• Diaz-Manera J, Kishnani PS, Kushlaf H, et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a Phase 3, randomised, multicentre trial. Lancet Neurol. 2021;20(12):1012–1026.
   PubMed Web of Science ®Google Scholar
• Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20(12):1027–1037.
   PubMed Web of Science ®Google Scholar
• Dimachkie MM, et al. Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset pompe disease. Neurology. 2022;99(5):e536–48.
   PubMed Web of Science ®Google Scholar
• Berrier KL, Barohn RJ, Byrne B. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. 2015;17(11):912–918.
   PubMed Web of Science ®Google Scholar
• Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2013;15(2):123–131.
   PubMed Web of Science ®Google Scholar
• Roger AL, Sethi R, Huston ML, et al. What’s new and what’s next for gene therapy in Pompe disease? Expert Opin Biol Ther. 2022;22(9):1117–1135.
   PubMed Web of Science ®Google Scholar
• Byrne PI, Smith B, Mah C, et al. Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease. Hum Gene Ther Clin Dev. 2014;25(3):134–163.
   PubMed Web of Science ®Google Scholar
• Smith BK, Collins SW, Conlon TJ, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther. 2013;24(6):630–640.
   PubMed Web of Science ®Google Scholar
• Smith EC, Hopkins S, Case LE, et al. Phase I study of liver depot gene therapy in late-onset Pompe disease. Mol Ther. 2023;2023:1.
   Google Scholar
• Hagemans ML, Winkel LP, Hop WC, et al. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005;64(12):2139–2141.
   PubMed Web of Science ®Google Scholar
• Silva PL, Rocco PRM. The basics of respiratory mechanics: ventilator-derived parameters. Ann Transl Med. 2018;6(19):376.
   PubMed Web of Science ®Google Scholar
• Johnson EM, Roberts M, Mozaffar T, et al. Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease. Neuromuscul Disord. 2016;26(2):136–145.
   PubMed Web of Science ®Google Scholar
• Khan A, Frazer-Green L, Amin R, et al. Respiratory management of patients with neuromuscular weakness: an American college of chest physicians clinical practice guideline and expert panel report. Chest. 2023;2023:1.
   Google Scholar
• NPPV Titration Task Force of the American Academy of Sleep Medicine. Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med. 2010;6(5):491–509.
   PubMed Web of Science ®Google Scholar
• Morelot-Panzini C, Bruneteau G, Gonzalez-Bermejo J. NIV in amyotrophic lateral sclerosis: the ‘when’ and ‘how’ of the matter. Respirology. 2019;24(6):521–530.
   PubMed Web of Science ®Google Scholar
• Mellies U, Dohna-Schwake C, Voit T. Respiratory function assessment and intervention in neuromuscular disorders. Curr Opin Neurol. 2005;18(5):543–547.
   PubMed Web of Science ®Google Scholar
• Jones HN, Crisp KD, Moss T, et al. Effects of respiratory muscle training (RMT) in children with infantile-onset Pompe disease and respiratory muscle weakness. J Pediatr Rehabil Med. 2014;7(3):255–265.
   PubMedGoogle Scholar
• Jones HN, Crisp KD, Robey RR, et al. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): effects of training and detraining. Mol Genet Metab. 2016;117(2):120–128.
   PubMed Web of Science ®Google Scholar
• Jones HN, Kuchibhatla M, Crisp KD, et al. Respiratory muscle training in late-onset Pompe disease: results of a sham-controlled clinical trial. Neuromuscul Disord. 2020;30(11):904–914. doi:10.1016/j.nmd.2020.09.023
   PubMed Web of Science ®Google Scholar
• Illi SK, Held U, Frank I, et al. Effect of respiratory muscle training on exercise performance in healthy individuals: a systematic review and meta-analysis. Sports Med. 2012;42(8):707–724. doi:10.1007/BF03262290
   PubMed Web of Science ®Google Scholar
• Wenninger S, Greckl E, Babačić H, et al. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study. J Neurol. 2019;266(1):133–147. doi:10.1007/s00415-018-9112-4
   PubMed Web of Science ®Google Scholar
• Jones HN, Moss T, Edwards L, et al. Increased inspiratory and expiratory muscle strength following respiratory muscle strength training (RMST) in two patients with late-onset Pompe disease. Mol Genet Metab. 2011;104(3):417–420. doi:10.1016/j.ymgme.2011.05.006
   PubMed Web of Science ®Google Scholar
• Jevnikar M, Metka K, Fabiana C, et al. Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease. Mol Genet Metab Rep. 2015;5:67–71. doi:10.1016/j.ymgmr.2015.09.007
   PubMedGoogle Scholar
• Ing RJ, Ryan Cook D, Bengur RA, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth. 2004;14(6):514–519. doi:10.1111/j.1460-9592.2004.01242.x
   PubMed Web of Science ®Google Scholar
• Walker RW, Briggs G, Bruce J, et al. Regional anesthetic techniques are an alternative to general anesthesia for infants with Pompe’s disease. Paediatr Anaesth. 2007;17(7):697–702. doi:10.1111/j.1460-9592.2007.02196.x
   PubMed Web of Science ®Google Scholar
• Al Atassi A, Al Zughaibi N, Naeim A, et al. Anesthesia management in an infant with glycogen storage disease type II (Pompe Disease). Middle East J Anaesthesiol. 2015;23(3):343–346.
   PubMedGoogle Scholar
• Wang LY, Ross AK, Li JS, et al. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. Paediatr Anaesth. 2007;17(8):738–748. doi:10.1111/j.1460-9592.2007.02215.x
   PubMed Web of Science ®Google Scholar
• McFarlane HJ, Soni N. Pompe’s disease and anaesthesia. Anaesthesia. 1986;41(12):1219–1224. doi:10.1111/j.1365-2044.1986.tb13007.x
   PubMedGoogle Scholar
• Edelstein G, Hirshman CA. Hyperthermia and ketoacidosis during anesthesia in a child with glycogen-storage disease. Anesthesiology. 1980;52(1):90–92. doi:10.1097/00000542-198001000-00025
   PubMed Web of Science ®Google Scholar
• Kotani N, Hashimoto H, Hirota K, et al. Prolonged respiratory depression after anesthesia for parathyroidectomy in a patient with juvenile type of acid maltase deficiency. J Clin Anesth. 1996;8(7):620. doi:10.1016/S0952-8180(96)00092-X
   PubMed Web of Science ®Google Scholar